18 January 2017
News and Views
Links and Services
Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease, reports the latest issue of Inflammatory Bowel Diseases.
Infliximab induces and maintains clinical remission in children with Crohn's disease (CD), but sp
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors